This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It's time for Drug Channels annual examination of U.S. brand-name drugpricing. For 2024, average brand-name drugs list prices grew by only 2.3%. Whats more, after adjusting for overall inflation, brand-name drug net prices dropped for an unprecedented seventh consecutive year.
As the debate over drugpricing intensifies, some proposals—like the Most Favored Nation model—may sound appealing in theory, but they carry serious unintended consequences.
Click here to see the original post from January 2025. It's time for Drug Channels annual examination of U.S. brand-name drugpricing. For 2024, average brand-name drugs list prices grew by only 2.3%. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.
Pharma marketing innovation is poised for an unprecedented surge in 2025, driven by new technologies, regulatory shifts, and evolving patient expectations. This article dives deep into why 2025 will mark a pivotal moment for pharma marketing and how savvy brands can stay ahead.
On May 8, 2025, the Court of Appeals for the Third Circuit affirmed the district courts dismissal of AstraZenecas challenges to the Inflation Reduction Acts DrugPrice Negotiation Program and CMSs Guidance implementing the Program.
24 Hours in the Hub Still Matters More Chris Dowd, ConnectiveRx June 16th 2025 Article Doubling down on patient access and support fundamentals will win out over Washington’s next move. Related Content Policy Whiplash?
Table of Contents Drug Approvals and Market Movers Digital Health and AI Integration Policy Changes and Global Regulations Marketing Trends in Pharma Advertising Drug Approvals and Market Movers Breakthrough therapies and new drug approvals regularly dominate pharma news. Why does this matter to marketers?
The situation may worsen if more drug companies follow suit in restricting 340B savings. As we enter 2025 Q2, the sad truth is that most 340B hospitals are struggling to protect their programs from further prescription-savings erosion. The Expanding Challenges of 340B in 2025 1.
The 340B DrugPricing Program has emerged as a growing source of profits for pharmacies and pharmacy benefit managers (PBMs). The 2025 market data below illustrate just how far the 340B program’s operations have diverged from its original intent. For more on what the 340B program’s growth means for pharmacies, join Adam J.
Minnesota just released the industry‘s first ever mandated financial report on the 340B DrugPricing Program. During next week’s Drug Channels Outlook 2025 live video webinar, he'll tell you what's ahead for the program that continues to defy gravity. There are important limitations to these data.
The NHC supports the efforts to reduce out-of-pocket costs for Medicare beneficiaries and appreciates CMS’ work to establish a process that seeks to incorporate patient perspectives into drugpricing policy. This will allow other stakeholders (e.g.,
It’s time for Drug Channels ’ annual update on drugpricing trends at the largest pharmaceutical manufacturers. When accounting for all list price reductions, average brand-name drugprices declined at four manufacturers and increased at five others. You can find links to each company’s data below.
Importantly, this type of insight also supports smarter negotiations around drugpricing. In communities where there is only one pharmacy – or none – there is no competition to drive down prices. By identifying these regions, PBMs can better advocate for fair pricing models that reflect real-world access challenges.
Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals DrugPricing Gene Therapy An article from Dive Brief Actithera draws new investors to radiopharma drug pitch The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.
AI in value-based pricing and RWE generation AI has the potential to transform value-based pricing (VBP) by leveraging machine learning for dynamic pricing models that adjust drugprices based on real-world patient outcomes. Serialization 2.0: Why It’s Time to Upgrade, and What’s at Stake John F.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drugprices? Abigail Beaney July 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The new legislation will reduce the time it takes for patients to receive these therapies from months to days.
Even though the PTE provisions established in the DrugPrice Competition and Patent Restoration Act are forty-plus years old, courts are still grappling with questions about how to best implement the Patent Term Extension. On March 13, 2025, the Federal Circuit ventured into the world of reissued patents and PTE. (
This article explores the key Pharma Marketing Challenges that define 2025—and what pharma brands must do to stay relevant, effective, and compliant. Scandals, misinformation, and aggressive drugpricing continue to erode confidence, even when products like Ozempic and DUPIXENT bring groundbreaking benefits.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drugprices? July 28, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HRS-9821 aligns with GSK’s goal to address a broad spectrum of COPD patients. Credit: OleksSH / Shutterstock.com.
Nicholas Saraceno Key Takeaways DSCSA enforcement deadlines are phasing in through 2025 , with wholesalers and repackagers already required to comply as of May 27, and wholesale distributors facing an August 27 deadline—provided they show active progress on data connections. The most recent enforcement delay came Oct.
Published June 16, 2025 Amy Baxter Staff Reporter post share post print email license Arkansas Gov. Arkansas became the first state in the nation to ban PBMs from owning pharmacies in 2025. Drugprices and what some states describe as anticompetitive behavior have prompted calls for action. Capitol on May 8, 2024.
How Recent Executive Orders Impact the DrugPricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drugpricing and market access.
Soefje, PharmD, MBA, BCOP, during the Hematology/Oncology Pharmacy Association (HOPA) 2025 Annual Conference in Portland, Oregon. This pathway’s expanded use and shifting Centers for Medicare & Medicaid Services (CMS) policies are reshaping reimbursement practices and therapeutic equivalence standards for 505(b)(2) drugs.
Pharmaceutical Industry (Washington, DC: Pharmaceutical Research and Manufacturers of America, April 22, 2025). Food and Drug Administration, Importing Biologics and CBER Regulated Products, accessed April 29, 2025, https ://www.fda.gov/industry/importing-fda-regulated-products/importing-biologics-and- cber-regulated-products.
According to Trump, patients could see cost reductions of 30% to 80%, but experts question the feasibility and practicality of implementing such a policy within the complex United States drugpricing and supply system. Kennedy Jr, is permitted to develop a new rule that ties American drugprices to those of other nations.
June 6, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The funds will support clinical milestones along with AI-driven development across Juvenescence’s portfolio. The acquisition forms a key part of Juvenescence’s partnership with the Abu Dhabi global healthcare company M42, which was announced in April 2025.
June 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The funds will be used to advance Mosanna’s nasal spray for obstructive sleep apnoea. Thank you for subscribing View all newsletters from across the GlobalData Media network. Login Registration is disabled.
accelerates its crackdown on drugpricing through new legislation and regulatory enforcement, pharma companies in China, India, Japan, and South Korea are feeling the ripple effect. This move marked a major shift in how drugpricing is managed in the United Statesa market that contributes significantly to global pharma revenues.
June 6, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The authorisation in the EU signifies a step forward in eye care for paediatric patients. Thank you for subscribing View all newsletters from across the GlobalData Media network. Login Registration is disabled.
How Recent Executive Orders Impact the DrugPricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drugpricing and market access.
Image Credit: Adobe Stock Images/Artur.com Key Takeaways Sanofi is shipping Beyfortus early to ensure strong supply for the 2025–2026 RSV season and avoid past shortages. Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season. June 9, 2025.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drugprices? GlobalData Healthcare July 28, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Credit: Vitalii Vodolazskyi / Shutterstock.com. Login Registration is disabled.
Image Credit: Adobe Stock Images/StockMediaLabs.com Evaluate, who provides market insights for the pharma industry, has unveiled its “2025 World Preview Report,” which offers insights for the global pharmaceutical market through the year 2030. June 23, 2025. Accessed June 23, 2025. June 17, 2025. Accessed June 23, 2025.
Alex Watt June 9, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The delays in market access in individual EU member states have been an obstacle to the industry. Credit: New Africa via Shutterstock. times more products than the overall European average. Login Registration is disabled.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drugprices? July 21, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The acquisition of Blueprint provides Sanofi with a well-established foothold among allergists, dermatologists and immunologists.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drugprices? July 24, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Updates in the ICH E6 (R3) guidelines refine the ways clinical trials are designed and operated. Credit: via Shutterstock.
June 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Enflonsia is administered to infants with the same dose regardless of their bodyweight. “We Thank you for subscribing View all newsletters from across the GlobalData Media network. Login Registration is disabled.
Published July 14, 2025 Ben Fidler Senior Editor post share post print email license Takeda reported positive results for oveporexton, a drug being developed for narcolepsy Type 1, on July 14, 2025. and elsewhere in its 2025 fiscal year and plans to present detailed results at an upcoming medical meeting. inhibitors.
24 Hours in the Hub Still Matters More June 16, 2025 By Chris Dowd, ConnectiveRx Commentary Article Pharmaceutical Commerce Pharmaceutical Commerce - June 2025 Volume 20 Issue 3 Doubling down on patient access and support fundamentals will win out over Washington’s next move. Chris Dowd Key Takeaways Speed is Critical.
Published June 26, 2025 Gwendolyn Wu Senior reporter post share post print email license B cells, like those pictured above, malfunction in autoimmune disease. Published June 26, 2025 Gwendolyn Wu Senior reporter post share post print email license B cells, like those pictured above, malfunction in autoimmune disease.
Frankie Fattorini July 1, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The EU Pharma Package’s attempt to balance priorities risks achieving none. UK-based Persica gained an EU patent for its lower back pain therapy PP353, which targets infections that underlie pain, in June 2025.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content